Myasthenia Gravis Clinical Trials 2024

What are the top hospitals conducting myasthenia gravis research?

When it comes to advancing the treatment options for myasthenia gravis, several hospitals are at the forefront of cutting-edge clinical trials. In sunny Tampa, Florida, the University of South Florida is making significant strides with four active trials dedicated to this complex autoimmune condition. With a total of eight previous myasthenia gravis studies under their belt since their first recorded trial in 2013, they have become a hub for innovative research in this field.

Heading north to Charleston, South carolina, we find the Medical University of South Carolina actively conducting three myasthenia gravis trials and building upon their six past investigations. Their journey into researching this neuromuscular disorder began in 2018 and has been instrumental in expanding our understanding of its complexities.

Meanwhile, out west in Kansas City at the University of Kansas Medical Center, researchers are also committed to finding new breakthroughs for myasthenia gravis. With three ongoing clinical trials and an impressive history of eleven completed studies since starting their first trial back in 2008, they continue to contribute valuable insights into this challenging disease.

Venturing outside the United States to Toronto General Hospital in Canada's vibrant cityscape highlights another noteworthy institution pioneering advancements for myasthenia gravis patients. This hospital showcases three current trials alongside seven previously conducted studies that began with their initial exploration into this condition back in 2011.

Finally adding itself into this mix is Clinical Trial Site located right here amidst Tampa where two ongoing tests while contributing towards over-all four lifetime attempts can bring hope through exploring fresh possibilities using recent technology which kick-started from year twenty-eighteen

These leading hospitals exemplify a commitment to uncovering new therapies and improving outcomes for individuals living with myasthenia gravis—a chronic illness affecting neuromuscular junctions causing muscle weakness or fatigue symptoms—by pushing boundaries through rigorous research endeavors. Together these institutions serve as beacons of hope for patients worldwide, offering the promise of better treatments and ultimately a brighter future.

Which are the best cities for myasthenia gravis clinical trials?

Chapel Hill, North carolina; Tampa, Florida; Los Angeles and Orange, California; and Philadelphia, Pennsylvania emerge as the top cities for myasthenia gravis clinical trials. Chapel Hill leads with 14 active trials exploring treatments like Efgartigimod, Eculizumab, and zilucoplan (RA101495). Following closely are Tampa with 12 trials studying Nipocalimab, Eculizumab, and zilucoplan (RA101495), along with Los Angeles and Orange tied at 11 trials investigating options such as Nipocalimab, Eculizumab, Satralizumab, inebilizumab. Lastly is Philadelphia with 10 ongoing studies focused on treatments like Eculizumab,Nipocalimab,and ALXN2050. These cities offer individuals battling myasthenia gravis access to a diverse range of cutting-edge clinical trials that hold promise for advancing treatment options and improving patient outcomes.

Which are the top treatments for myasthenia gravis being explored in clinical trials?

Exciting developments are underway in the realm of myasthenia gravis treatment, with several top contenders showcasing their potential in ongoing clinical trials. Nipocalimab takes center stage, participating in two active trials and marking its entry into this field in 2021. Acupuncture also emerges as a promising avenue, with one active trial providing insights into its efficacy since it was first listed as a treatment option in 2022. ALXN2050 and robotic-assisted surgery round out the lineup, each showing promise through one active trial and making their mark on the myasthenia gravis landscape in 2021 and 2022 respectively. These cutting-edge approaches hold great hope for patients navigating the challenges of this complex condition.

What are the most recent clinical trials for myasthenia gravis?

Exciting advancements are being made in the field of myasthenia gravis, as recent clinical trials offer new hope for patients. One notable trial is investigating the effectiveness of rozanolixizumab administered through a syringe driver or manual push. This Phase 3 study aims to evaluate its potential benefits in managing this condition. Additionally, another Phase 1 trial focuses on MuSK-CAART, which may hold promise as a treatment option specifically for myasthenia gravis patients with muscle-specific kinase (MuSK) antibodies. ALXN1720 and zilucoplan are also being studied in separate Phase 3 trials to assess their efficacy against myasthenia gravis symptoms. Moreover, efgartigimod is undergoing both Phase 2 and Phase 3 trials, further exploring its potential benefits for those with this autoimmune disorder. These innovative clinical trials bring renewed optimism to individuals living with myasthenia gravis by expanding our understanding and potential treatment options for this challenging condition.

What myasthenia gravis clinical trials were recently completed?

Recent clinical trials in the realm of myasthenia gravis have made significant strides towards advancing treatment options for this autoimmune disorder. In February 2021, argenx completed a trial investigating efgartigimod PH20 SC with promising outcomes. Another noteworthy trial was conducted by Takeda, which concluded in January 2020 and focused on evaluating TAK-079 as a potential therapy for myasthenia gravis. Additionally, Ra Pharmaceuticals' zilucoplan (RA101495) trial wrapped up in September 2019, followed closely by Alexion's Ravulizumab study and argenx's ARGX-113 trial both completing in March of the same year. These pivotal trials illuminate the commitment of researchers to push boundaries and provide hope for individuals grappling with myasthenia gravis.